Lower antibody functionality in middle-aged adults compared to adolescents after primary meningococcal vaccination: Role of IgM
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
van der Heiden, Mariekevan Ravenhorst, Mariette B
Bogaard, Marjan
Boots, Annemieke MH
Berbers, Guy AM
Buisman, Anne-Marie
Language
en
Metadata
Show full item recordTitle
Lower antibody functionality in middle-aged adults compared to adolescents after primary meningococcal vaccination: Role of IgMPublished in
Expl Gerontol 2018; 105:101-8Publiekssamenvatting
Successful vaccination of elderly persons is often hampered by immunological ageing, leaving part of the elderly population vulnerable for infectious diseases. As an alternative, timely vaccinations might be administered at middle-age, before reaching old age. Studies evaluating the immunological fitness of middle-aged adults are warranted. In this study we compared the immunogenicity of a primary meningococcal vaccination in Dutch middle-aged adults with that in adolescents, in order to gain knowledge on the early signs of immune ageing.PMID
29287771ae974a485f413a2113503eed53cd6c53
10.1016/j.exger.2017.12.014
Scopus Count
Collections
Related articles
- Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
- Authors: van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM
- Issue date: 2017 Aug 24
- Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
- Authors: Borja-Tabora CF, Montalban C, Memish ZA, Boutriau D, Kolhe D, Miller JM, Van der Wielen M
- Issue date: 2015 Oct 6
- Novel Intervention in the Aging Population: A Primary Meningococcal Vaccine Inducing Protective IgM Responses in Middle-Aged Adults.
- Authors: van der Heiden M, Boots AMH, Bonacic Marinovic AA, de Rond LGH, van Maurik M, Tcherniaeva I, Berbers GAM, Buisman AM
- Issue date: 2017
- Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
- Authors: van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Knol MJ, Stoof SP, Sanders EAM, Berbers GAM
- Issue date: 2017 Aug 24
- Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.
- Authors: van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM
- Issue date: 2019 Jan 5